Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 63Cardiovascular Diseases 3Neoplasms 2Stage II Prostate Adenocarcinoma 1Sarcopenia 1Prostatic Neoplasms, Castration-Resistant 1Prostatectomy 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Osteoporosis 1Oligometastatic Prostate Carcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Metabolic Syndrome 1Metabolic Diseases 1Eunuchism 1Diabetes Mellitus 1Dementia 1Cognitive Dysfunction 1Advanced Prostate Cancer 1

Interventions

enzalutamide 1Prednisone 1Lysine Acetyltransferase 5 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dementia × Gonadotropin-Releasing Hormone × Genitourinary × Clear all
NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Northwestern University

Phase 4 Active not recruiting
100 enrolled
Genitourinary

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡